Fabino Enterprises Ltd vs Vilin Bio Med Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Fabino Enterprises Ltd is ₹ 20.31 as of 27 Apr 15:30 . The P/E Ratio of Fabino Enterprises Ltd is 600 as of March 2023 .The P/E Ratio of Vilin Bio Med Ltd is 0 as of March 2023 . The Market Cap of Fabino Enterprises Ltd is ₹ 6.3 crore as of March 2023 .The Market Cap of Vilin Bio Med Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vilin Bio Med Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

About Vilin Bio Med Ltd

Vilin Bio Med Limited was originally incorporated on June 29, 2005, which commenced business on July 11, 2005 issued by Registrar of Companies, Andhra Pradesh, Hyderabad.
The Company started its first commercial production in 2006.
In 2007, the Company expanded the Phase 2 for Beta Lactum facility with 16000 sft for Tablet, Capsule and Dry Syrup sections.
In 2010, it acquired more than 1000 molecules Drug Approvals with different strengths in therapeutics of Diabetic, Neuro and Cardio. The Company added the Sachet section in Non-Beta Lactum facility in 2014.
The Company allotted a fresh issue of 40,00,000 Equity Shares of Rs 10/- each by its Initial Public Offering by raising funds aggregating to Rs 12 Crore on June 7, 2023. At present, Company is engaged in domestic business of manufacturing Pharmaceuticals products and the Manufacturing Unit is located in Roorkee, in the State of Uttarakhand.

FAQs for the comparison of Fabino Enterprises Ltd and Vilin Bio Med Ltd

Which company has a larger market capitalization, Fabino Enterprises Ltd or Vilin Bio Med Ltd?

Market cap of Fabino Enterprises Ltd is 4 Cr while Market cap of Vilin Bio Med Ltd is 65 Cr

What are the key factors driving the stock performance of Fabino Enterprises Ltd and Vilin Bio Med Ltd?

The stock performance of Fabino Enterprises Ltd and Vilin Bio Med Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fabino Enterprises Ltd and Vilin Bio Med Ltd?

As of May 5, 2026, the Fabino Enterprises Ltd stock price is INR ₹20.31. On the other hand, Vilin Bio Med Ltd stock price is INR ₹42.75.

How do dividend payouts of Fabino Enterprises Ltd and Vilin Bio Med Ltd compare?

To compare the dividend payouts of Fabino Enterprises Ltd and Vilin Bio Med Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.